D712BB1
Brachytherapy Spleen to Unidirectional Source with Palladium 103 (Pd-103), Low Dose Rate (LDR) Approach
Procedural Specifications
| Clinical Axis | Detail Definition |
|---|---|
| Section | D Radiation Therapy |
| Body System | 7 Lymphatic and Hematologic System |
| Operation | 1 Brachytherapy |
| Body Part | 2 Spleen |
| Approach | B Low Dose Rate (LDR) |
| Device | B Palladium 103 (Pd-103) |
| Qualifier | 1 Unidirectional Source |
Procedure Overview
Brachytherapy of the lymphatic and hematologic system involves placing a radioactive source directly into or adjacent to lymphatic tissue, delivering a concentrated, localized dose while sparing tissue farther from the source. This is less common than external beam treatment for this body system but may be used for localized nodal disease where direct source placement offers better dose control, or in combination with surgery for residual microscopic tumor at a nodal bed.
The radioactive material can be left in place temporarily and removed after a calculated dose is delivered, or in some cases placed permanently as small seeds that decay over time. The approach is chosen when the anatomic target allows safe, direct access for source placement.
Anatomy & Axis Detail
Spleen
Brachytherapy of the spleen involves placing a radioactive source directly at or within splenic tissue, an infrequent approach reserved for situations where a highly localized dose is needed, such as a discrete splenic lesion, rather than treatment of the diffusely enlarged organ typically managed with external beam radiation. Given the spleen's rich vascularity and friable capsule, implant placement carries meaningful bleeding risk and is generally performed under image guidance or in conjunction with a surgical approach to the abdomen. The proximity of the left kidney, stomach, and diaphragm further constrains source positioning and dwell time. This localized technique is chosen specifically when sparing the remainder of splenic tissue or adjacent organs from a broader radiation field is a priority, and documentation should reflect the focal nature of the implant.
Modality Qualifier: Low Dose Rate (LDR)
Low Dose Rate (LDR) denotes brachytherapy using a source of lower activity that remains implanted or applied over an extended period, from many hours to a few days, exploiting continuous low-level irradiation for tumor control. This differs from High Dose Rate (HDR), which compresses the same general goal into brief, higher-intensity sessions, and LDR is often chosen for permanent seed implants such as certain prostate treatments.
Isotope: Palladium 103 (Pd-103)
Palladium-103 is another low-dose-rate isotope used in permanent interstitial seed implants, chiefly for prostate brachytherapy, but its shorter half-life (about 17 days) delivers its therapeutic dose faster than I-125. Clinicians may favor it for higher-grade or faster-growing tumors where a more concentrated early dose is desired, while I-125 remains preferred for lower-risk, slower disease.
Qualifier: Unidirectional Source
This qualifier specifies that a unidirectional radioactive source is used in radiation therapy, meaning the source emits radiation in one direction rather than uniformly, as with certain brachytherapy applicators. It distinguishes this directional delivery technique from standard radiation sources, which do not require this added qualifying detail.
Coding & Documentation
Coders confirm brachytherapy by finding documentation of a radioactive source being implanted, inserted, or applied directly at or near the lymphatic target, along with whether the source was temporary or permanent, which determines the correct approach and qualifier values. The radiation oncology or interventional procedure note should specify the isotope, source configuration, and duration of placement.
A frequent mistake is confusing a temporary applicator left in place for a planned removal with a permanent seed implant, which changes both the qualifier and the expected follow-up documentation. Coders should also verify the treated body part matches the nodal region named in the operative note rather than assuming it based on the underlying diagnosis.